Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Risk adjusted net present value: What is the current valuation of Fusion Pharmaceuticals's FPI-2265?
FPI-2265 is a small molecule commercialized by Fusion Pharmaceuticals, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer...
FPI-2265 by Fusion Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
FPI-2265 is under clinical development by Fusion Pharmaceuticals and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Risk adjusted net present value: What is the current valuation of Fusion Pharmaceuticals's FPI-2265?
FPI-2265 is a small molecule commercialized by Fusion Pharmaceuticals, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer...